ScoreWhy is Xeris Biopharma Holdings, Inc. ?
1
With a growth in Net Sales of 13.93%, the company declared Outstanding results in Mar 26
- The company has declared positive results for the last 6 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at USD 48.52 MM
- PRE-TAX PROFIT(Q) At USD 2.23 MM has Grown at 1,513%
- NET PROFIT(Q) At USD 2.23 MM has Grown at 1,513%
2
With ROE of 4.05%, it has a attractive valuation with a 68.02 Price to Book Value
- Over the past year, while the stock has generated a return of 51.75%, its profits have risen by 101% ; the PEG ratio of the company is 9.2
3
High Institutional Holdings at 69.21%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
4
Market Beating performance in long term as well as near term
- Along with generating 51.75% returns in the last 1 year, the stock has outperformed S&P 500 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Xeris Biopharma Holdings, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Xeris Biopharma Holdings, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Xeris Biopharma Holdings, Inc.
52.99%
3.46
57.69%
S&P 500
25.41%
1.92
13.25%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
70.19%
EBIT Growth (5y)
18.17%
EBIT to Interest (avg)
-5.59
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-5.05
Sales to Capital Employed (avg)
0.98
Tax Ratio
5.40%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
69.21%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
931
Industry P/E
Price to Book Value
68.02
EV to EBIT
42.04
EV to EBITDA
27.84
EV to Capital Employed
8.10
EV to Sales
3.59
PEG Ratio
9.23
Dividend Yield
NA
ROCE (Latest)
19.27%
ROE (Latest)
4.05%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend25What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD 48.52 MM
PRE-TAX PROFIT(Q)
At USD 2.23 MM has Grown at 1,513%
NET PROFIT(Q)
At USD 2.23 MM has Grown at 1,513%
NET SALES(HY)
At USD 168.93 MM has Grown at 40.52%
RAW MATERIAL COST(Y)
Fallen by -3.81% (YoY
DEBTORS TURNOVER RATIO(HY)
Highest at 6.14 times
-3What is not working for the Company
INVENTORY TURNOVER RATIO(HY)
Lowest at 0.87 times
DEBT-EQUITY RATIO
(HY)
Highest at 1,128.3 %
Here's what is working for Xeris Biopharma Holdings, Inc.
Pre-Tax Profit
At USD 2.23 MM has Grown at 1,513%
over average net sales of the previous four periods of USD 0.14 MMMOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (USD MM)
Net Profit
At USD 2.23 MM has Grown at 1,513%
over average net sales of the previous four periods of USD 0.14 MMMOJO Watch
Near term Net Profit trend is very positive
Net Profit (USD MM)
Operating Cash Flow
Highest at USD 48.52 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Net Sales
At USD 168.93 MM has Grown at 40.52%
Year on Year (YoY)MOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Debtors Turnover Ratio
Highest at 6.14 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by -3.81% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Depreciation
Highest at USD 3.21 MM
in the last five periodsMOJO Watch
The expenditure on assets done by the company may have gone into operation
Depreciation (USD MM)
Here's what is not working for Xeris Biopharma Holdings, Inc.
Inventory Turnover Ratio
Lowest at 0.87 times and Fallen
In each half year in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling inventory has slowed
Inventory Turnover Ratio
Debt-Equity Ratio
Highest at 1,128.3 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
